Singular Genomics Systems, Inc.: Nasdaq/NYSE listing notice — Singular Genomics transfers to Nasdaq Capital Market; gets 180 days to regain $1 bid price

Singular Genomics Systems, Inc.

Approval received Jan 16, 2024; transfer effective Jan 18, 2024, to Nasdaq Capital Market under symbol OMIC.
Company was non-compliant with Nasdaq's $1.00 minimum bid price requirement since July 17, 2023.
Granted 180-day compliance period until July 15, 2024; must close at $1.00+ for 10 consecutive business days.
If compliance not achieved, Nasdaq will delist; company may effect reverse stock split if necessary.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Singular Genomics Systems, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

al Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. As previously disclosed, on July 17, 2023, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its common stock from the Nasdaq Glob

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-24-005804

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.